Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
GAITHERSBURG, Md., March 07, 2018 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will provide a corporate update and report its fourth quarter and full year 2017 financial and operating results following the close of U.S. financial markets on Wednesday, March 14, 2018.
| Conference call and webcast details are as follows: | |
| Date: | March 14, 2018 |
| Time: | 5:00 p.m. U.S. Eastern Time (ET) |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
| Passcode: | 6472939 |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
| Conference call and webcast replay: | |
| Dates: | Starting at 8:00 p.m. ET, March 14, 2018 until |
| 9:00 p.m. ET March 21, 2018 | |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) |
| Passcode: | 6472939 |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until June 14, 2018 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Our RSV and influenza nanoparticle vaccine candidates are Novavax’ most advanced clinical programs and are at the forefront of the Company’s efforts to improve global health. Additional information about Novavax is available on the Company's website, novavax.com.
Contact:
Investors
Westwicke Partners
John Woolford
[email protected]
443-213-0506
Media
Sam Brown
Mike Beyer
[email protected]
312-961-2502
